DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Jones J, Andritsos L, Kreitman RJ, Ravandi F, Schiffer C, Call TG. et al.
Efficacy and safety of the Bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: Stage 1 results of a phase 2 study.
Blood 2016;
128: 1215
Access:
We do not assume any responsibility for the contents of the web pages of other providers.